CDEK
← All organizations

Intercept Pharmaceuticals

For profitContributed to NMEWebsite ↗

Also known as: Intercept Pharmaceticals, Inc. | Intercept Pharmaceuticals | Intercept Pharmaceuticals - Chief Medical Officer | Intercept Pharmaceuticals, Inc | Intercept Pharmaceuticals, Inc. | Intercept Pharmaceuticals, San Diego, CA 92122 | INTERCEPT PHARMS INC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Jul 1, 2007

First marketed drug

May 27, 2016

First NDA

May 27, 2016

Last known activity

Jul 1, 2024

Acquired by Alfasigma S.p.A. on Sep 26, 2023

Timeline

2000s

  1. Jan 1, 2002

    Intercept Pharmaceuticals— Founded

2010s

  1. May 27, 2016

    obeticholic acid— NDA Organization

  2. May 27, 2016

    obeticholic acid— NDA Secondary Org

2020s

  1. Sep 26, 2023

    Alfasigma S.p.A.— Acquired By

Drugs by trial phase (6 distinct, 23 trials)

Phase 4 (1 own, 0 via acquisition)

Phase 3 (1 own, 0 via acquisition)

Phase 2 (4 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (1)

Recent trials (41)

Details

Founded
New York, NY, US Jan 1, 2002
First NDA
May 27, 2016
Last known activity
Jul 1, 2024

Designations held

  • Orphan drug
  • Fast track
  • Priority review
  • Accelerated approval